Skip to main content

Physiological Roles and Therapeutic Implications of Hepatocyte Growth Factor for Angiogenesis

  • Chapter
  • First Online:
Biochemical Basis and Therapeutic Implications of Angiogenesis

Part of the book series: Advances in Biochemistry in Health and Disease ((ABHD,volume 6))

  • 1765 Accesses

Abstract

Angiogenesis is an important event for organ development and regeneration via supply of nutrition and oxygen. Appropriate cellular responses, such as endothelial cell (EC) growth, are involved in the angiogenic actions, especially under hypoxic conditions. Hepatocyte growth factor (HGF) is now an organotrophic factor that is essential for organ development and tissue regeneration. In addition, HGF is the most potent angiogenic growth factor in culture of ECs, with mitogenic, and morphogenic functions via activation of c-Met/HGF-receptor. In hypoxic diseases, such as coronary arterial disease (CAD), up-regulation of HGF production is transient, followed by the HGF-deficient conditions, along with the lowered angiogenesis and enhanced hypoxia. Enhancement of angiogenesis by exogenous HGF leads to the improvement in heart dysfunction. Such angio-therapeutic effects of HGF are also seen in various hypoxic diseases, such as skin ulcer and lung emphysema. In tumor tissues, angiogenesis is required for cancer growth and metastasis. Indeed, an HGF-antagonist, NK4, potently inhibits tumor angiogenesis and metastasis in mouse models of malignant tumors. These provide a rationale why HGF is useful for the improvement in CAD and other ischemic diseases and NK4 for the suppression of tumor malignancy. Importantly, appropriate HGF-c-Met signal is required for sustaining homeostasis in normal tissue. Herein, we provide a concept that amount of HGF may determine the predisposition to ischemic disease, healthy conditions, or neoplastic disease, all of which depend on the degree of c-Met activation, and in part, concomitant angiogenic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ando J, Kamiya A (1993) Blood flow and vascular endothelial cell function. Front Med Biol Eng 5:245–264

    PubMed  CAS  Google Scholar 

  2. Staudacher DL, Preis M, Lewis BS et al (2006) Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol Ther 109:263–273

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

    Article  PubMed  CAS  Google Scholar 

  4. Nakamura T, Nawa K, Ichihara A (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122:1450–1459

    Article  PubMed  CAS  Google Scholar 

  5. Nakamura T, Nawa K, Ichihara A et al (1987) Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 224:311–316

    Article  PubMed  CAS  Google Scholar 

  6. Nakamura T, Nishizawa T, Hagiya M et al (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440–443

    Article  PubMed  CAS  Google Scholar 

  7. Tashiro K, Hagiya M, Nishizawa T et al (1990) Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci USA 87:3200–3204

    Article  PubMed  CAS  Google Scholar 

  8. Dean M, Park M, Le Beau MM et al (1985) The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318:385–388

    Article  PubMed  CAS  Google Scholar 

  9. Bottaro DP, Rubin JS, Faletto DL et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804

    Article  PubMed  CAS  Google Scholar 

  10. Higuchi O, Mizuno K, Vande Woude GF, Nakamura T (1992) Expression of c-met proto-­oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor. FEBS Lett 301:282–286

    Article  PubMed  CAS  Google Scholar 

  11. Schaeper U, Gehring NH, Fuchs KP et al (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149:1419–1432

    Article  PubMed  CAS  Google Scholar 

  12. Nakamura T, Mizuno S (2010) The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 86:588–610

    Article  PubMed  CAS  Google Scholar 

  13. Ishiki Y, Ohnishi H, Muto Y et al (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16:1227–1235

    PubMed  CAS  Google Scholar 

  14. Honda S, Kagoshima M, Wanaka A et al (1995) Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res 32:197–210

    Article  PubMed  CAS  Google Scholar 

  15. Nakamura T, Mizuno S, Matsumoto K et al (2000) Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106:1511–1519

    Article  PubMed  CAS  Google Scholar 

  16. Bussolino F, Di Renzo MF, Ziche M et al (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641

    Article  PubMed  CAS  Google Scholar 

  17. Nakamura Y, Morishita R, Nakamura S et al (1996) A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28:409–413

    Article  PubMed  CAS  Google Scholar 

  18. Morishita R, Aoki M, Hashiya N et al (2004) Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 4:199–206

    Article  PubMed  CAS  Google Scholar 

  19. Matsumoto K, Nakamura T (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94:321–327

    Article  PubMed  CAS  Google Scholar 

  20. Montesano R, Matsumoto K, Nakamura T, Orci L (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901–908

    Article  PubMed  CAS  Google Scholar 

  21. Nakamura Y, Morishita R, Higaki J et al (1995) Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 215:483–488

    Article  PubMed  CAS  Google Scholar 

  22. Machide M, Hashigasako A, Matsumoto K, Nakamura T (2006) Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 281:8765–8772

    Article  PubMed  CAS  Google Scholar 

  23. Ding S, Merkulova-Rainon T, Han ZC et al (2003) HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 101:4816–4822

    Article  PubMed  CAS  Google Scholar 

  24. Scarpino S, Cancellario d’Alena F, Di Napoli A et al (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358

    Article  PubMed  CAS  Google Scholar 

  25. Morishita R, Nakamura S, Hayashi S et al (1999) Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33:1379–1384

    Article  PubMed  CAS  Google Scholar 

  26. Hayashi S, Morishita R, Nakamura S et al (1999) Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100:II301–II308

    Article  PubMed  CAS  Google Scholar 

  27. Nakagami H, Morishita R, Yamamoto K et al (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37:581–586

    Article  PubMed  CAS  Google Scholar 

  28. Van Belle E, Witzenbichler B, Chen D et al (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97:381–390

    Article  PubMed  Google Scholar 

  29. Liu Y, Wilkinson FL, Kirton JP et al (2007) Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. J Pathol 212:12–19

    Article  PubMed  CAS  Google Scholar 

  30. Martin TA, Mansel R, Jiang WG (2001) Hepatocyte growth factor modulates vascular endothelial-­cadherin expression in human endothelial cells. Clin Cancer Res 7:734–737

    PubMed  CAS  Google Scholar 

  31. Grant DS, Kleinman HK, Goldberg ID et al (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937–1941

    Article  PubMed  CAS  Google Scholar 

  32. Wang H, Keiser JA (2000) Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem Biophys Res Commun 272:900–905

    Article  PubMed  CAS  Google Scholar 

  33. Purdie KJ, Whitley GS, Johnstone AP, Cartwright JE (2002) Hepatocyte growth factor- induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression. Cardiovasc Res 54:659–668

    Article  PubMed  CAS  Google Scholar 

  34. Aoyagi M, Yamamoto S, Azuma H et al (1999) Localization and effects of hepatocyte growth factor on smooth muscle cells during neointimal formation after balloon denudation. Histochem Cell Biol 111:419–428

    Article  PubMed  CAS  Google Scholar 

  35. Taher TE, Derksen PW, de Boer OJ et al (2002) Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun 298:80–86

    Article  PubMed  CAS  Google Scholar 

  36. Kobayashi H, DeBusk LM, Babichev YO et al (2006) Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 108:1260–1266

    Article  PubMed  CAS  Google Scholar 

  37. Zhao J, Wang W, Ha CH et al (2011) Endothelial Grb2-associated binder 1 is crucial for postnatal angiogenesis. Arterioscler Thromb Vasc Biol 31:1016–1023

    Article  PubMed  CAS  Google Scholar 

  38. Kanda S, Kanetake H, Miyata Y (2006) HGF-induced capillary morphogenesis of endothelial cells is regulated by Src. Biochem Biophys Res Commun 344:617–622

    Article  PubMed  CAS  Google Scholar 

  39. Somlyo AV, Phelps C, Dipierro C et al (2003) Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 17:223–234

    Article  PubMed  CAS  Google Scholar 

  40. Morishita R, Nakamura S, Nakamura Y et al (1997) Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46:138–142

    Article  PubMed  CAS  Google Scholar 

  41. Liu F, Schaphorst KL, Verin AD et al (2002) Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J 16:950–962

    Article  PubMed  CAS  Google Scholar 

  42. Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG (2007) HGF attenuates thrombin-­induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J 21:2776–2786

    Article  PubMed  CAS  Google Scholar 

  43. Singleton PA, Salgia R, Moreno-Vinasco L et al (2007) CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem 282:30643–30657

    Article  PubMed  CAS  Google Scholar 

  44. Birukova AA, Cokic I, Moldobaeva N, Birukov KG (2009) Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol 40:99–107

    Article  PubMed  CAS  Google Scholar 

  45. Kim I, Moon SO, Kim SH et al (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276:7614–7620

    Article  PubMed  CAS  Google Scholar 

  46. Kaga T, Kawano H, Sakaguchi M et al (2012) Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 57:3–9

    Article  PubMed  CAS  Google Scholar 

  47. Mizuno S, Nakamura T (2005) Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys. Am J Pathol 166:1895–1905

    Article  PubMed  CAS  Google Scholar 

  48. Min JK, Lee YM, Kim JH et al (2005) Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 96:300–307

    Article  PubMed  CAS  Google Scholar 

  49. Kamimoto M, Mizuno S, Matsumoto K, Nakamura T (2009) Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun 380:333–337

    Article  PubMed  CAS  Google Scholar 

  50. Hayashi S, Morishita R, Higaki J et al (1996) Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun 220:539–545

    Article  PubMed  CAS  Google Scholar 

  51. Kuba K, Matsumoto K, Date K et al (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743

    PubMed  CAS  Google Scholar 

  52. Rush S, Khan G, Bamisaiye A et al (2007) c-jun amino-terminal kinase and mitogen activated protein kinase 1/2 mediate hepatocyte growth factor-induced migration of brain endothelial cells. Exp Cell Res 313:121–132

    Article  PubMed  CAS  Google Scholar 

  53. Soeki T, Tamura Y, Shinohara H et al (2000) Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 15:105–111

    Article  PubMed  CAS  Google Scholar 

  54. Zhu Y, Hojo Y, Ikeda U, Shimada K (2000) Production of hepatocyte growth factor during acute myocardial infarction. Heart 83:450–455

    Article  PubMed  CAS  Google Scholar 

  55. Ono K, Matsumori A, Shioi T et al (1997) Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95:2552–2558

    Article  PubMed  CAS  Google Scholar 

  56. Aoki M, Morishita R, Taniyama Y et al (2000) Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7:417–427

    Article  PubMed  CAS  Google Scholar 

  57. Nakamura T, Matsumoto K, Mizuno S et al (2005) Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 288:H2131–H2139

    Article  PubMed  CAS  Google Scholar 

  58. Li Y, Takemura G, Kosai K et al (2003) Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 107:2499–2506

    Article  PubMed  CAS  Google Scholar 

  59. Jayasankar V, Woo YJ, Pirolli TJ et al (2005) Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg 20:93–101

    Article  PubMed  Google Scholar 

  60. Yamaguchi T, Sawa Y, Miyamoto Y et al (2005) Therapeutic angiogenesis induced by injecting hepatocyte growth factor in ischemic canine hearts. Surg Today 35:855–860

    Article  PubMed  CAS  Google Scholar 

  61. Taniyama Y, Morishita R, Aoki M et al (2002) Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40:47–53

    Article  PubMed  CAS  Google Scholar 

  62. Yasuda S, Noguchi T, Gohda M et al (2000) Single low-dose administration of human recombinant hepatocyte growth factor attenuates intimal hyperplasia in a balloon-injured rabbit iliac artery model. Circulation 101:2546–2549

    Article  PubMed  CAS  Google Scholar 

  63. Hayashi K, Nakamura S, Morishita R et al (2000) In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 7:1664–1671

    Article  PubMed  CAS  Google Scholar 

  64. Bessho K, Mizuno S, Matsumoto K, Nakamura T (2003) Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol Renal Physiol 284:F1171–F1180

    PubMed  CAS  Google Scholar 

  65. Sanada F, Taniyama Y, Iekushi K et al (2009) Negative action of hepatocyte growth factor/c-­Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 105:667–675

    Article  PubMed  CAS  Google Scholar 

  66. Mizuno S, Matsumoto K, Li MY, Nakamura T (2005) HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 19:580–582

    PubMed  Google Scholar 

  67. Mizuno S, Nakamura T (2012) Improvement of sepsis by hepatocyte growth factor, an anti-­inflammatory regulator: emerging insights and therapeutic potential. Gastroenterol Res Pract 2012:909350

    Google Scholar 

  68. Yoshitomi Y, Kojima S, Umemoto T et al (1999) Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 84:2425–2428

    Article  PubMed  CAS  Google Scholar 

  69. Yoshida S, Matsumoto K, Tomioka D et al (2004) Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 22:111–119

    Article  PubMed  CAS  Google Scholar 

  70. Taniyama Y, Morishita R, Hiraoka K et al (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104:2344–2350

    Article  PubMed  CAS  Google Scholar 

  71. Vajanto I, Rissanen TT, Rutanen J et al (2002) Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4:371–380

    Article  PubMed  CAS  Google Scholar 

  72. Tsuzuki N, Miyazawa T, Matsumoto K et al (2001) Hepatocyte growth factor reduces the infarct volume after transient focal cerebral ischemia in rats. Neurol Res 23:417–424

    Article  PubMed  CAS  Google Scholar 

  73. Yoshimura S, Morishita R, Hayashi K et al (2002) Gene transfer of hepatocyte growth factor to subarachnoid space in cerebral hypoperfusion model. Hypertension 39:1028–1034

    Article  PubMed  CAS  Google Scholar 

  74. Shimamura M, Sato N, Oshima K et al (2004) Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 109:424–431

    Article  PubMed  CAS  Google Scholar 

  75. Date I, Takagi N, Takagi K et al (2004) Hepatocyte growth factor attenuates cerebral ischemia-­induced learning dysfunction. Biochem Biophys Res Commun 319:1152–1158

    Article  PubMed  CAS  Google Scholar 

  76. Miyazawa T, Matsumoto K, Ohmichi H et al (1998) Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Cereb Blood Flow Metab 18:345–348

    Article  PubMed  CAS  Google Scholar 

  77. Takeuchi D, Sato N, Shimamura M et al (2008) Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther 15:561–571

    Article  PubMed  CAS  Google Scholar 

  78. Ono M, Sawa Y, Matsumoto K et al (2002) In vivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation 106:I264–I269

    PubMed  Google Scholar 

  79. Shigemura N, Sawa Y, Mizuno S et al (2005) Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation 111:1407–1414

    Article  PubMed  CAS  Google Scholar 

  80. Ishizawa K, Kubo H, Yamada M et al (2004) Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun 324:276–280

    Article  PubMed  CAS  Google Scholar 

  81. Ono M, Sawa Y, Mizuno S et al (2004) Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 110:2896–2902

    Article  PubMed  CAS  Google Scholar 

  82. Mizuno S, Nakamura T (2011) Hydrodynamics, Chap 6. In: Schulz HA, Anfrade AL, Lobosco RJ (eds) Endocrine delivery system of NK4, an HGF antagonistic and anti-­angiogenic regulator, for controlling tumor growth and metastasis, 1st edn. InTECH publisher, Rijeka, Croatia, pp 119–142

    Google Scholar 

  83. Kajiya K, Hirakawa S, Ma B et al (2005) Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24:2885–2895

    Article  PubMed  CAS  Google Scholar 

  84. Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718–12723

    Article  PubMed  CAS  Google Scholar 

  85. Lee WJ, Chen WK, Wang CJ et al (2008) Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226:178–191

    Article  PubMed  CAS  Google Scholar 

  86. Tsarfaty G, Stein GY, Moshitch-Moshkovitz S et al (2006) HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia 8:344–352

    Article  PubMed  CAS  Google Scholar 

  87. Jiang WG, Martin TA, Matsumoto K et al (1999) Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol 181:319–329

    Article  PubMed  CAS  Google Scholar 

  88. Date K, Matsumoto K, Shimura H et al (1997) HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420:1–6

    Article  PubMed  CAS  Google Scholar 

  89. Matsumoto K, Kataoka H, Date K, Nakamura T (1998) Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem 273:22913–22920

    Article  PubMed  CAS  Google Scholar 

  90. Laterra J, Nam M, Rosen E et al (1997) Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76:565–577

    PubMed  CAS  Google Scholar 

  91. Jiang WG, Hiscox SE, Parr C et al (1999) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5:3695–3703

    PubMed  CAS  Google Scholar 

  92. Matsumoto K, Matsumoto K, Nakamura T, Kramer RH (1994) Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 269:31807–31813

    PubMed  CAS  Google Scholar 

  93. Nakamura T, Matsumoto K, Kiritoshi A et al (1997) Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57:3305–3313

    PubMed  CAS  Google Scholar 

  94. Date K, Matsumoto K, Kuba K et al (1998) Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 17:3045–3054

    Article  PubMed  CAS  Google Scholar 

  95. Tomioka D, Maehara N, Kuba K et al (2001) Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61:7518–7524

    PubMed  CAS  Google Scholar 

  96. Wen J, Matsumoto K, Taniura N et al (2004) Hepatic gene expression of NK4, an HGF-­antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11:419–430

    Article  PubMed  CAS  Google Scholar 

  97. Suzuki Y, Sakai K, Ueki J et al (2010) Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 127:1948–1957

    Article  PubMed  CAS  Google Scholar 

  98. Matsumoto K, Nakamura T (2005) Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 333:316–327

    Article  PubMed  CAS  Google Scholar 

  99. Kikuchi T, Maemondo M, Narumi K et al (2002) Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood 100:3950–3959

    Article  PubMed  CAS  Google Scholar 

  100. Hirao S, Yamada Y, Koyama F et al (2002) Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther 9:700–707

    Article  PubMed  CAS  Google Scholar 

  101. Namiki Y, Namiki T, Yoshida H et al (2006) Preclinical study of a “tailor-made” combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118:1545–1555

    Article  PubMed  CAS  Google Scholar 

  102. Brockmann MA, Papadimitriou A, Brandt M et al (2003) Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578–4585

    PubMed  CAS  Google Scholar 

  103. Heideman DA, Overmeer RM, van Beusechem VW et al (2005) Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther 12:954–962

    Article  PubMed  CAS  Google Scholar 

  104. Du W, Hattori Y, Yamada T et al (2007) NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109:3042–3049

    Article  PubMed  CAS  Google Scholar 

  105. Saga Y, Mizukami H, Suzuki M et al (2001) Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 8:1450–1455

    Article  PubMed  CAS  Google Scholar 

  106. Davies G, Mason MD, Martin TA et al (2003) The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348–354

    Article  PubMed  CAS  Google Scholar 

  107. Sakai K, Nakamura T, Matsumoto K, Nakamura T (2009) Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 284:22491–22499

    Article  PubMed  CAS  Google Scholar 

  108. Siltanen A, Kitabayashi K, Lakkisto P et al (2011) hHGF overexpression in myoblast sheets enhances their angiogenic potential in rat chronicheart failure. PLoS One 6:e19161

    Article  PubMed  CAS  Google Scholar 

  109. Buchstein N, Hoffmann D, Smola H et al (2009) Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am J Pathol 174:2116–2128

    Article  PubMed  CAS  Google Scholar 

  110. Nayeri F, Strömberg T, Larsson M et al (2002) Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study. J Dermatolog Treat 13:81–86

    Article  PubMed  CAS  Google Scholar 

  111. Shigematsu H, Yasuda K, Iwai T et al (2010) Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 17:1152–1161

    Article  PubMed  CAS  Google Scholar 

  112. Makino H, Aoki M, Hashiya N et al (2012) Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 32:2503–2509

    Google Scholar 

  113. Yuan B, Zhao Z, Zhang YR et al (2008) Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In Vivo 22:629–632

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Ministry of Education, Science, Technology, Sports and Culture of Japan (No. 23590458 to S.M. and No. 21390079 and Global COE program to T.N.). We also thank Mrs. Yoshiko Yoneda for secretarial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshikazu Nakamura .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ohnishi, H., Mizuno, S., Oka, K., Nakamura, T. (2013). Physiological Roles and Therapeutic Implications of Hepatocyte Growth Factor for Angiogenesis. In: Mehta, J., Dhalla, N. (eds) Biochemical Basis and Therapeutic Implications of Angiogenesis. Advances in Biochemistry in Health and Disease, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5857-9_22

Download citation

Publish with us

Policies and ethics